Cargando…
Pediatric Prolonged-Release Melatonin for Sleep in Children with Autism Spectrum Disorder: Impact on Child Behavior and Caregiver’s Quality of Life
A randomized, 13-weeks, placebo-controlled double-blind study in 125 subjects aged 2–17.5 years with Autism Spectrum Disorder or Smith-Magenis syndrome and insomnia demonstrated efficacy and safety of easily-swallowed prolonged-release melatonin mini-tablets (PedPRM; 2–5 mg) in improving sleep durat...
Autores principales: | Schroder, Carmen M., Malow, Beth A., Maras, Athanasios, Melmed, Raun D., Findling, Robert L., Breddy, John, Nir, Tali, Shahmoon, Shiri, Zisapel, Nava, Gringras, Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647439/ https://www.ncbi.nlm.nih.gov/pubmed/31079275 http://dx.doi.org/10.1007/s10803-019-04046-5 |
Ejemplares similares
-
Long-Term Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children with Autism Spectrum Disorder
por: Maras, Athanasios, et al.
Publicado: (2018) -
Sleep, Growth, and Puberty After 2 Years of Prolonged-Release Melatonin in Children With Autism Spectrum Disorder
por: Malow, Beth A., et al.
Publicado: (2020) -
Prolonged release melatonin for improving sleep in totally blind subjects: a pilot placebo-controlled multicenter trial
por: Roth, Thomas, et al.
Publicado: (2015) -
Prolonged-release melatonin for insomnia – an open-label long-term study of efficacy, safety, and withdrawal
por: Lemoine, Patrick, et al.
Publicado: (2011) -
Efficacy and safety of prolonged-release melatonin for insomnia in middle-aged and elderly patients with hypertension: a combined analysis of controlled clinical trials
por: Lemoine, Patrick, et al.
Publicado: (2012)